The effect of zoledronic acid (Zol) dose and infusion rate on pharmacolkinetics (PK), pharmacodynamics (PD), and renal function in patients (pts) with multiple myeloma (MM) or prostate cancer (PC) and bone metastases. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Major, Pierre
  • Berenson, J
  • Swift, R
  • Vescio, R
  • Ravera, C
  • Bilic, S
  • Gauron, S
  • Denouel, J
  • Schran, H

publication date

  • June 1, 2005